𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A double-blind placebo-controlled trial ofl-threonine in amyotrophic lateral sclerosis

✍ Scribed by O. Blin; J. Pouget; G. Aubrespy; C. Guelton; A. Crevat; G. Serratrice

Publisher
Springer
Year
1992
Tongue
English
Weight
295 KB
Volume
239
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A placebo-controlled trial of recombinan
A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis
✍ Dr. Robert G. Miller; Jack H. Petajan; Wilson W. Bryan; Carmel Armon; Richard J. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 474 KB 👁 1 views

There is no satisfactory treatment for amyotrophic lateral sclerosis (ALS) [ 11. Ciliary neurotrophic factor (CNTF) is an endogenous protein that is released upon injury to the nervous system and limits the extent of injury-induced tieuronal damage in some nerve cells [2, 31. CNTF can be produced in

Glatiramer acetate in primary progressiv
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
✍ Jerry S. Wolinsky; Ponnada A. Narayana; Paul O'Connor; Patricia K. Coyle; Corey 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 349 KB 👁 2 views

## Abstract ## Objective To determine whether glatiramer acetate (GA) slows accumulation of disability in primary progressive multiple sclerosis. ## Methods A total of 943 patients with primary progressive multiple sclerosis were randomized to GA or placebo (PBO) in this 3‐year, double‐blind tri

γ-Vinyl GABA: A double-blind placebo-con
γ-Vinyl GABA: A double-blind placebo-controlled trial in partial epilepsy
✍ Dr Lennart Gram; Peter Klosterskov; Mogens Dam 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 1 views

## Abstract The antiepileptic effect of γ‐vinyl γ‐aminobutyric acid (GABA), an irreversible GABA‐transaminase inhibitor, was investigated in an add‐on, placebo‐controlled, double‐blind, cross‐over, fixed‐dose trial. Twenty‐one patients suffering from difficult to control complex partial seizures pa